EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience

İbrahim Halil Açar iD, Birol Güvenç

Hematology Reports · 02.08.2023 · 15 (3) · 465-473

DOI: 10.3390/hematolrep15030048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 02.08.2023. Verfasst von İbrahim Halil Açar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Osmaniye State Hospital, 80000 Osmaniye, Turkey. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Relapsed/refractory extramedullary myeloma (RREMM) is an uncommon and aggressive subtype of multiple myeloma defined by plasma cell proliferation outside the bone marrow. Therapeutic options for RREMM are limited, and the prognosis is generally unfavorable. This research aimed to assess the effectiveness of the bendamustine, pomalidomide, and dexamethasone (BPD) regimen in patients with RREMM. Material and Methods: We carried out a retrospective investigation of 11 RREMM patients who underwent BPD treatment. The primary endpoint was progression-free survival. The secondary endpoints of the study were two-year survival and overall response rate (ORR). We analyzed the sociodemographic and clinical features of the patients.

Results

The average age of the patients was 62 years. They had a median of four prior treatment lines, and eight patients had previously received autologous stem-cell transplantation. After eight BPD treatment cycles, the ORR stood at 54%, with one very good partial response (VGPR), five partial responses (PR), three progressive diseases (PD), and two stable diseases (SD). The median follow-up was 15 months, with a two-year PFS rate of 71.3% and a two-year survival rate of 81.8%.

Conclusions

The BPD regimen demonstrated promising effectiveness in RREMM patients, yielding favorable ORR and survival rates. To corroborate these findings and explore additional treatment alternatives for this patient group, larger prospective studies are required.

Schlagwörter

Stichwörter der Autor:innen

bendamustinedexamethasonemultiple myelomapomalidomiderelapsed/refractory extramedullary myelomatreatment outcomes

Autor:innen und Institutionen

  • Department of Hematology, Osmaniye State Hospital, 80000 Osmaniye, Turkey.
  • Department of Hematology, Çukurova University, 01330 Adana, Turkey.

ORCID-Profile: İbrahim Halil Açar

Zitieren

APA

Açar, İ. H., & Güvenç, B. (2023). Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience. Hematology Reports, 15(3), 465-473. https://doi.org/10.3390/hematolrep15030048

Vancouver

Açar İH, Güvenç B. Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience. Hematology Reports. 2023;15(3):465-473. doi:10.3390/hematolrep15030048

BibTeX
@article{Aar2023,
  author = {Açar, İbrahim Halil and Güvenç, Birol},
  title = {Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience},
  journal = {Hematology Reports},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {465--473},
  doi = {10.3390/hematolrep15030048}
}
Kostenlos starten →